account* Says decided goals of Qnexa study with FDA * Plans to resubmit Qnexa marketing approval in Q4 as lmtd indication * Q1 loss per shr $0.12 vs est $0.15 * Shares up 6 pct after-market (Follows alerts) May 2 (Reuters) - Drugmaker...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Vivus to submit Qnexa application as limited indication, shares up
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account